CluenexPenumbra PEN
Penumbra scores good on business quality (7.0 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Penumbra does
Penumbra designs and sells medical devices for interventional stroke and vascular treatments, selling directly to hospitals and physicians.
- What it does best
Penumbra dominates niche vascular thrombectomy markets with specialized aspiration devices. Revenue growth hits 17.5%, placing it in the top quartile of its sector at the 86th percentile. This rapid expansion outpaces peers like GEHC at 4.8%, driven by specialized clinical adoption that is difficult for rivals to displace.
- The main risk
Trading at a steep price of 317.55 against an intrinsic value of 142.95, the market prices in perfection. Any growth stumble or competitive pressure from peers like ZBH could trigger a severe multiple contraction.
Quality, check by check
Scored against its own industry, from company filings.
Operating margin sits at 12.4% while FCF margin reaches 53%. Profitability is improving alongside revenue scale, though operating margins trail some large-cap device peers.
Penumbra relies on physician preference and specialized device design to lock in hospitals. However, a modest moat score of 4.6 and a gross margin percentile of 59 reflect limited pricing power against established medtech giants.
Revenue reached 1.5 billion, growing at 17.5% annually. This accelerates from historical figures like 1.2 billion in 2024, driven by strong adoption of its core vascular devices.
Penumbra holds 545 million in cash against just 23 million in debt, backed by an interest coverage of 144x. Free cash flow reached 216 million, marking a very strong balance sheet.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
No open market buys or unplanned sales by executives or directors.
Our sealed record on PEN
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Penumbra scores good on the Cluenex quality check (7.0 of 10), measured against its own industry. Profitability is weak, moat fair, growth fast and financial health strong.
In the last 90 days of SEC Form 4 filings: No open market buys or unplanned sales by executives or directors.
Nov 4, 2026, after the close.
See PEN today
- Today's verdict on PEN, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Penumbra (PEN)”, https://cluenex.com/stocks/pen/, data as of Oct 10, 2026.